Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Idiopathic pulmonary fibrosis primarily occurs in older adults and disease confined to lungs only. Symptoms may include weight loss, pneumonia, fatigue, low-gradefevers and others. Idiopathic pulmonary fibrosis diagnosis is done through imaging techniques, lung biopsy,laboratory tests and others. Currently, no medications are proven to effectively treat idiopathic pulmonary fibrosis. Generally, Azathioprine, Prednisone,and N-acetyl cysteine are used alone or combination for the treatment.

 

Segmentation:

By route of administration, Idiopathic Pulmonary pipeline drugs are segmented into

  • Inhalation
  • Parenteral
  • Others

By Trial Phase, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

By Company, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:

  • Johnson & Johnson Services, Inc. (U.S.)
  • ImmuneWorks, Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (U.S.)
  • Biogen, Inc. (U.S.)
  • FibroGen (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Promedior, Inc. (U.S)

 

Space Analysis:

Many of the research studies and ongoing trials are studying the various drugs and lead molecules to treat the idiopathic pulmonary fibrosis. The recognition of new factors contributing to the pathogenesis of idiopathic pulmonary fibrosis has led to the development of novel approaches to treat idiopathic pulmonary fibrosis.

  • In August 2017, FibroGen, Inc. announced positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
  • In October 2017, Prometic Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).

 

Report Description:

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Idiopathic Pulmonary Fibrosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Idiopathic Pulmonary Fibrosis disease pipeline drugs development. This report studies the dynamics of the Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Idiopathic Pulmonary Fibrosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases

 

  • Johnson & Johnson Services, Inc. (U.S.)
  • ImmuneWorks, Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (U.S.)
  • Biogen, Inc. (U.S.)
  • FibroGen (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Promedior, Inc. (U.S)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553